Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SNPX

Synaptogenix Inc

Dec 12 • 04:00PM ET

2.68

Dollar change -0.29
Percentage change -9.76	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB ACAD AXSM PRTA SAVA ALEC ANVS AUPH CMPS CABA

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.45	Insider Own	1.95%	Shs Outstand	1.36M	Perf Week	-9.46%
Market Cap	3.63M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.33M	Perf Month	-10.67%
Income	-9.13M	PEG	-	EPS next Q	-	Inst Own	1.88%	Short Float	0.54%	Perf Quarter	-15.19%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-4.27%	Short Ratio	0.33	Perf Half Y	-38.67%
Book/sh	9.44	P/B	0.28	EPS next Y	-	ROA	-29.78%	Short Interest	0.01M	Perf Year	-57.89%
Cash/sh	16.29	P/C	0.16	EPS next 5Y	-	ROE	-41.57%	52W Range	2.32 - 8.77	Perf YTD	-60.57%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.59%	ROI	-71.34%	52W High	-69.46%	Beta	1.40
Dividend TTM	-	Quick Ratio	65.36	Sales past 5Y	0.00%	Gross Margin	-	52W Low	15.52%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	65.36	EPS Y/Y TTM	71.73%	Oper. Margin	-	RSI (14)	43.59	Volatility	6.74% 9.00%
Employees	8	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	14.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-442.81%	Payout	-	Rel Volume	0.66	Prev Close	2.97
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Aug 02	Avg Volume	21.83K	Price	2.68
SMA20	-2.89%	SMA50	-8.68%	SMA200	-31.22%	Trades		Volume	14,326	Change	-9.76%

Sep-11-24 09:00AM	Synaptogenix Announces $5.0 Million Financing (PR Newswire) -19.21%
Aug-16-24 09:52PM	SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024 (InvestorPlace)
Jul-18-24 09:00AM	Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury (PR Newswire)
Jun-26-24 09:00AM	Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis (PR Newswire)
May-20-24 11:54AM	SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024 (InvestorPlace)
09:00AM	Loading…
May-07-24 09:00AM	Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery (PR Newswire)
Apr-24-24 09:15AM	Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing (PR Newswire)
Apr-09-24 09:15AM	Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics (PR Newswire) -8.35%
Apr-03-24 08:00AM	Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing (PR Newswire)
Dec-19-23 09:00AM	Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders (PR Newswire) +5.45%
Dec-06-23 09:00AM	Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's (PR Newswire)
Nov-02-23 09:00AM	Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology (PR Newswire)
Sep-26-23 09:00AM	Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease (PR Newswire) +5.67%
Sep-07-23 09:00AM	Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study (PR Newswire) -12.23%
Jul-19-23 09:00AM	Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis (PR Newswire)
09:00AM	Loading…
Jul-13-23 09:00AM	Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience (PR Newswire) +20.79%
Mar-07-23 09:00AM	Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities (PR Newswire)
Dec-16-22 09:00AM	Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease (PR Newswire) -74.63%
Nov-18-22 09:00AM	Synaptogenix Announces $15 Million Private Placement with Existing Investors (PR Newswire) +12.72%
Oct-19-22 09:00AM	Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022 (PR Newswire)
Sep-28-22 11:50AM	Synaptogenix Welcomes Lecanemab Phase 3 Trial Results (PR Newswire)
Aug-12-22 09:00AM	Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network (PR Newswire) +5.10%
Jul-26-22 09:15AM	Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data (PR Newswire) +6.37%
Jul-21-22 09:15AM	Synaptogenix Announces Corporate Update Conference Call (PR Newswire)
Jul-20-22 09:15AM	Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data (PR Newswire) +5.81%
May-17-22 09:15AM	Synaptogenix to Present at the Cell Symposium (PR Newswire) +10.97%
Apr-19-22 09:15AM	Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial (PR Newswire) -5.69%
Apr-05-22 09:15AM	New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease (PR Newswire)
Mar-29-22 09:15AM	Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit (PR Newswire)
Mar-22-22 09:15AM	Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum (PR Newswire)
09:15AM	Loading…
Mar-15-22 09:15AM	Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022) (PR Newswire)
Feb-23-22 09:15AM	Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis (PR Newswire)
Feb-07-22 09:38AM	Orion Capital Management LLC Buys Qualcomm Inc, Distillate U.S. ... (GuruFocus.com) -5.88%
Feb-01-22 09:15AM	Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients (PR Newswire) +29.36%
Dec-06-21 11:58AM	We're Hopeful That Synaptogenix (NASDAQ:SNPX) Will Use Its Cash Wisely (Simply Wall St.)
Sep-28-21 09:00AM	Synaptogenix Announces Participation at the Benzinga Healthcare Small Cap Conference (PR Newswire)
Sep-10-21 09:00AM	Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-05-21 10:00AM	Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome (PR Newswire) -6.18%
Jul-26-21 09:15AM	Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021 (PR Newswire) -19.09%
Jul-21-21 09:00AM	Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings (PR Newswire) +19.86%
Jul-14-21 09:00AM	Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline (PR Newswire) +9.74%
Jul-07-21 09:00AM	Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease (PR Newswire) -13.16%
Jun-24-21 09:00AM	Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network (PR Newswire)
Jun-14-21 09:00AM	Synaptogenix Announces $12.5 Million Private Placement (PR Newswire)
Jun-09-21 09:00AM	Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update (PR Newswire)
05:38AM	Is Synaptogenix (NASDAQ:SNPX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-19-21 09:00AM	Synaptogenix Announces Plan to Uplist on the Nasdaq Stock Market (PR Newswire)
May-10-21 09:00AM	Synaptogenix, Inc: Invitation to the Benzinga Global Small Cap Conference (Newsfile) -12.50%
Apr-26-21 09:00AM	Synaptogenix to Present at Sachs 4th Annual Neuroscience Innovation Forum (PR Newswire) +7.60%
Apr-01-21 09:00AM	Synaptogenix Announces Phase 2b Bryostatin-1 Clinical Trial Update (PR Newswire)
Mar-05-21 09:00AM	Synaptogenix to Present at the H.C. Wainwright Global Life Sciences Conference (PR Newswire) -8.16%
Feb-25-21 09:12AM	Synaptogenix to Present at Upcoming Scientific Industry Conferences (PR Newswire)
Feb-12-21 09:00AM	Synaptogenix to Participate in the Winter Wonderland - Best Ideas from the Buy-Side Conference (PR Newswire)
Feb-09-21 09:00AM	Synaptogenix Files Application to List on the Nasdaq Stock Market (PR Newswire) +20.83%

Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer's disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson's Disease, Traumatic Brain Injury, and Stroke. The company was founded on October 31, 2012 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNPX

Synaptogenix Inc

Upgrade your FINVIZ experience